These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30714880)

  • 21. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial.
    Liebschutz JM; Crooks D; Herman D; Anderson B; Tsui J; Meshesha LZ; Dossabhoy S; Stein M
    JAMA Intern Med; 2014 Aug; 174(8):1369-76. PubMed ID: 25090173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: a pilot randomized clinical trial.
    Chawarski MC; Mazlan M; Schottenfeld RS
    Drug Alcohol Depend; 2008 Apr; 94(1-3):281-4. PubMed ID: 18164145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Video directly observed therapy for patients receiving office-based buprenorphine - A pilot randomized controlled trial.
    Tsui JI; Leroux BG; Radick AC; Schramm ZA; Blalock K; Labelle C; Heerema M; Klein JW; Merrill JO; Saxon AJ; Samet JH; Kim TW
    Drug Alcohol Depend; 2021 Oct; 227():108917. PubMed ID: 34399136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.
    Presnall NJ; Wolf DAPS; Brown DS; Beeler-Stinn S; Grucza RA
    J Subst Abuse Treat; 2019 Sep; 104():135-143. PubMed ID: 31370977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study.
    Moore BA; Barry DT; Sullivan LE; Oʼconnor PG; Cutter CJ; Schottenfeld RS; Fiellin DA
    J Addict Med; 2012 Sep; 6(3):205-11. PubMed ID: 22614936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Supportive alternate site provision of buprenorphine: Overcoming barriers and improving patient outcomes.
    Khan A; Khan Q; Kolb E
    J Subst Abuse Treat; 2021 Apr; 123():108256. PubMed ID: 33612191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
    Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
    JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
    Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
    JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.
    Korthuis PT; King C; Cook RR; Khuyen TT; Kunkel LE; Bart G; Nguyen T; Thuy DT; Bielavitz S; Nguyen DB; Tam NTM; Giang LM
    Lancet HIV; 2021 Feb; 8(2):e67-e76. PubMed ID: 33539760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions.
    Ling S; Mangaoil R; Cleverley K; Sproule B; Puts M
    Drug Alcohol Depend; 2019 Apr; 197():168-182. PubMed ID: 30831429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Office-Based Addiction Treatment Retention and Mortality Among People Experiencing Homelessness.
    Fine DR; Lewis E; Weinstock K; Wright J; Gaeta JM; Baggett TP
    JAMA Netw Open; 2021 Mar; 4(3):e210477. PubMed ID: 33662132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of adjunctive, personalised psychosocial intervention for non-response to opioid agonist treatment: Study protocol for a pragmatic randomised controlled trial.
    Marsden J; Stillwell G; Hellier J; Brown AM; Byford S; Kelleher M; Kelly J; Murphy C; Shearer J; Mitcheson L
    Contemp Clin Trials; 2017 Feb; 53():36-43. PubMed ID: 27940188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do people with opioid use disorder and posttraumatic stress disorder benefit from dding Individual opioid Drug Counseling to buprenorphine?
    McHugh RK; Hilton BT; Chase AM; Griffin ML; Weiss RD
    Drug Alcohol Depend; 2021 Nov; 228():109084. PubMed ID: 34607194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
    JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone.
    Barry DT; Savant JD; Beitel M; Cutter CJ; Moore BA; Schottenfeld RS; Fiellin DA
    J Addict Med; 2012 Dec; 6(4):274-9. PubMed ID: 23041680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initiating buprenorphine treatment for opioid use disorder during short-term in-patient 'detoxification': a randomized clinical trial.
    Stein M; Herman D; Conti M; Anderson B; Bailey G
    Addiction; 2020 Jan; 115(1):82-94. PubMed ID: 31430414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network.
    Wu LT; John WS; Ghitza UE; Wahle A; Matthews AG; Lewis M; Hart B; Hubbard Z; Bowlby LA; Greenblatt LH; Mannelli P;
    Addiction; 2021 Jul; 116(7):1805-1816. PubMed ID: 33428284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pilot study assessing acceptability and feasibility of hatha yoga for chronic pain in people receiving opioid agonist therapy for opioid use disorder.
    Uebelacker LA; Van Noppen D; Tremont G; Bailey G; Abrantes A; Stein M
    J Subst Abuse Treat; 2019 Oct; 105():19-27. PubMed ID: 31443887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
    Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
    Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.